New blood test detects CRC advanced adenomas, study says

Freenome's novel multiomics blood test for colorectal cancer detected advanced adenomas with a 41 percent sensitivity at 90 percent specificity, according to results from its Ai-Emerge study.

Researchers examined results from 522 patients during the study. Compared to the FDA-approved mSEPT9 blood test, Freenome's test had a higher sensitivity (41 percent to 22 percent).

Compared to stool-based tests, Freenome's sensitivity for advanced adenomas outperformed fecal immunochemical testing (24 percent) and was comparable to FIT-DNA testing (42 percent).

The new results supplement previously reported data that showed Freenome's test detected stage 1 and stage 2 CRC at a sensitivity of 94 percent and a specificity of 94 percent.

More articles on surgery centers:
Ohio health system acquires surgery center for $21M
2 Texas health systems suspend surgeries, others don't
Stryker's ASC-focused business: 3 things to know

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Featured Webinars

Featured Whitepapers